The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.
 
Richard D. Baird
Research Funding - AstraZeneca (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Genentech (Inst); Molecular Partners (Inst); Roche (Inst); Sanofi (Inst); Shionogi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Molecular Partners; Shionogi
 
Annelot Van Rossum
No Relationships to Disclose
 
Mafalda Oliveira
Research Funding - AstraZeneca
 
Karin Beelen
No Relationships to Disclose
 
Javier Garcia-Corbacho
Consulting or Advisory Role - Shionogi
Travel, Accommodations, Expenses - Shionogi
 
Ingrid A M Mandjes
No Relationships to Disclose
 
Anne-Laure Vallier
No Relationships to Disclose
 
Erik D. van Werkhoven
No Relationships to Disclose
 
Sanjeev Srinivas Kumar
No Relationships to Disclose
 
Harm van Tinteren
No Relationships to Disclose
 
Emma Beddowes
No Relationships to Disclose
 
Hilde Rosing
No Relationships to Disclose
 
Mariette Schrier
No Relationships to Disclose
 
Aurelia de Vries Schultink
No Relationships to Disclose
 
Cristina Saura
No Relationships to Disclose
 
Rene Bernards
No Relationships to Disclose
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck; Merck Serono; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
Javier Cortes
Employment - MedSIR
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Roche/Genentech
Consulting or Advisory Role - Celgene; Roche/Genentech
 
Carlos Caldas
Research Funding - Genentech (Inst)
 
Sabine C. Linn
Research Funding - Genentech (Inst)